Meeting
2018 Gastrointestinal Cancers Symposium
A randomized phase III clinical trial of sequential capecitabine or 5-FU plus bevacizumab (Cape/5-FU+Bmab) followed by Cape/5-FU plus oxaliplatin plus Bmab (CapeOX/mFOLFOX6+Bmab) versus combination CapeOX/mFOLFOX6+Bmab in advanced colorectal cancer: The C-cubed (C3) study.
Authors
Hitoshi Ojima
Gunma Prefectural Cancer Center, Gunma, Japan
Hitoshi Ojima , Hideyuki Mishima , Akira Sawaki , Takeshi Nagasaka , Mototsugu Shimokawa , Michio Inukai , Katsunori Shinozaki , Hiroaki Tanioka , Junichiro Nasu , Tomohiro Nishina , Shoichi Hazama , Masazumi Okajima , Akihito Tsuji , Yasushi Tsuji , Yoshinori Munemoto , Shigeki Yamaguchi , Yoshiyuki Yamaguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
000015405
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr TPS872)
DOI
10.1200/JCO.2018.36.4_suppl.TPS872
Abstract #
TPS872
Poster Bd #
P24
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
CD276-positive circulating endothelial cells in advanced colorectal cancer.
First Author: Elske C. Gootjes
Poster
2018 Gastrointestinal Cancers Symposium
VOICE trial: Final results from multicenter phaseII study of assessment of clinical efficiency and safety in capecitabine plus intermittent oxaliplatin together with bevacizumab as first-line therapy for patients with advanced colorectal cancer.
First Author: Chihiro Kosugi
Poster
2012 Gastrointestinal Cancers Symposium
Phase II intermittent (or stop and go) l-OHP administration of first-line bevacizumab (BV) plus mFOLFOX6 or CapeOX therapies in Japanese patients with mCRC: The interim report of t-CORE0901.
First Author: Makio Gamoh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
First Author: Zev A. Wainberg